Skip to main navigation

About
- Team
- Contact
Research & Development
Pipeline
Investors
Careers

Press Releases

Press Releases

Year

May 10, 2021

Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress

May 3, 2021

Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting

April 21, 2021

Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors

March 11, 2021

Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021

March 9, 2021

Revolution Medicines to Participate in Upcoming Investor Conferences

March 2, 2021

Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress

February 18, 2021

Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences

February 8, 2021

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

February 3, 2021

Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock

February 1, 2021

Revolution Medicines Announces Proposed Public Offering of Common Stock

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page
Last page

Displaying 31 - 40 of 87

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2022 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063
CCPA Notice | Privacy Policy

Search Investor Relations